261715-36-0 Usage
General Description
3-Pyridinecarbonitrile,6-(methylamino)-(9CI) is a chemical compound with the molecular formula C8H7N3. It is a derivative of pyridine, and its structure includes a nitrile group and a methylamino group. This chemical is a pale yellow to brown solid at room temperature and is primarily used as an intermediate in the production of pharmaceuticals and agrochemicals. It is known to have potential biological activity and may be used as a building block for the synthesis of various organic compounds. It is important to handle this chemical with care, as it may pose health and environmental hazards if not managed properly.
Check Digit Verification of cas no
The CAS Registry Mumber 261715-36-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,6,1,7,1 and 5 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 261715-36:
(8*2)+(7*6)+(6*1)+(5*7)+(4*1)+(3*5)+(2*3)+(1*6)=130
130 % 10 = 0
So 261715-36-0 is a valid CAS Registry Number.
261715-36-0Relevant articles and documents
COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
-
Page/Page column 126, (2014/06/11)
The present invention provides compounds of formula I: [INSERT FORMULA HERE] or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease, such as malaria, caused by a Plasmodium parasite.
PIPERAZINYL DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES
-
Page/Page column 87-88, (2008/06/13)
The invention relates to compounds of formula (I), processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions or disorders which are mediated via the GPR38 receptor.
